{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T17:54:05Z","timestamp":1793555645700,"version":"4.5.0"},"reference-count":180,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a group of rare systemic diseases affecting small-caliber vessels. The damage caused by AAV mainly involves the lung and kidneys. AAV includes three different types: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Although the different phenotypic forms of AAV share common features, recent studies have shown that there are significant differences in terms of pathogenetic mechanisms involving both the adaptive and innate immune systems. Advances in our understanding of pathogenesis have enabled the development of immuno-targeted therapies. This review illustrates the characteristics of the various forms of AAV and the new therapies available for this disease that can have lethal consequences if left untreated.<\/jats:p>","DOI":"10.3390\/antib12010025","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T06:56:48Z","timestamp":1679381808000},"page":"25","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-9128","authenticated-orcid":false,"given":"Marino","family":"Paroli","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-2571","authenticated-orcid":false,"given":"Chiara","family":"Gioia","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Accapezzato","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_3","first-page":"12","article-title":"Drug-induced vasculitis: A clinical and pathological review","volume":"70","author":"Radic","year":"2012","journal-title":"Neth. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-Associated Vasculitis: Core Curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102716","DOI":"10.1016\/j.autrev.2020.102716","article-title":"The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis","volume":"20","author":"Guchelaar","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-113-9-656","article-title":"Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network","volume":"113","author":"Falk","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes","volume":"68","author":"Tryfon","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/art.41986","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis with Polyangiitis","volume":"74","author":"Robson","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"624848","DOI":"10.3389\/fimmu.2021.624848","article-title":"Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Update: Genetic Pathogenesis","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1093\/rheumatology\/kez597","article-title":"Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway","volume":"59","author":"Nilsen","year":"2020","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","article-title":"Global epidemiology of vasculitis","volume":"18","author":"Watts","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/rheumatology\/kep304","article-title":"Incidence and survival rates in Wegener\u2019s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa","volume":"48","author":"Mohammad","year":"2009","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1093\/rheumatology\/keaa924","article-title":"New insights into the epidemiology of ANCA-associated vasculitides in Germany: Results from a claims data study","volume":"60","author":"Hellmich","year":"2021","journal-title":"Rheumatology"},{"key":"ref_18","first-page":"243","article-title":"Churg-Strauss syndrome: Evolving concepts","volume":"9","author":"Pagnoux","year":"2010","journal-title":"Discov. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0","article-title":"Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom","volume":"43","author":"Watts","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_20","first-page":"589","article-title":"The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink","volume":"56","author":"Pearce","year":"2017","journal-title":"Rheumatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/ard.60.12.1156a","article-title":"Epidemiology of vasculitis in Europe","volume":"60","author":"Watts","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10067-016-3232-y","article-title":"The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey","volume":"35","author":"Pamuk","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.40313","article-title":"The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study","volume":"69","author":"Berti","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/art.11115","article-title":"The epidemiology of the primary systemic vasculitides in northwest Spain: Implications of the Chapel Hill Consensus Conference definitions","volume":"49","author":"Guerrero","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejim.2020.01.011","article-title":"ANCA associated vasculitis","volume":"74","author":"Salvador","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kem022","article-title":"Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener\u2019s granulomatosis","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1038\/s41467-019-11255-0","article-title":"A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic autoimmunity","volume":"10","author":"Ooi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener\u2019s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/rheumatology\/kex001","article-title":"Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate","volume":"56","author":"Salmela","year":"2017","journal-title":"Rheumatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.autrev.2013.06.016","article-title":"The association between silica exposure and development of ANCA-associated vasculitis: Systematic review and meta-analysis","volume":"12","author":"Gedmintas","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Takeuchi, Y., Saito, A., Ojima, Y., Kagaya, S., Fukami, H., Sato, H., Matsuda, K., and Nagasawa, T. (2017). The influence of the Great East Japan earthquake on microscopic polyangiitis: A retrospective observational study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0177482"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0272-6386(00)70260-5","article-title":"Significantly high regional morbidity of MPO-ANCA-related angitis and\/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan)","volume":"35","author":"Yashiro","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imj.13246","article-title":"Incidence of anti-neutrophil cytoplasmic antibody-associated vasculitis before and after the February 2011 Christchurch Earthquake","volume":"47","author":"Farquhar","year":"2017","journal-title":"Intern. Med. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.1780330802","article-title":"The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum."},{"key":"ref_35","first-page":"16","article-title":"Indirect immunofluorescence examination for IgG-ANCA in sera submitted for the 1st international workshop on ANCA, 1988","volume":"6","author":"Rasmussen","year":"1989","journal-title":"APMIS Suppl."},{"key":"ref_36","first-page":"185416","article-title":"Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies","volume":"2014","author":"Radice","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ajcp\/111.4.507","article-title":"International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)","volume":"111","author":"Savige","year":"1999","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2014.01.028","article-title":"Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener\u2019s granulomatosis)","volume":"48\u201349","author":"Lutalo","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2010.04.003","article-title":"Microscopic polyangiitis","volume":"36","author":"Chung","year":"2010","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fimmu.2014.00549","article-title":"Eosinophilic granulomatosis with polyangiitis: An overview","volume":"5","author":"Gioffredi","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BOR.0000000000000916","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis","volume":"35","author":"Yazici","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/art.38036","article-title":"Association of granulomatosis with polyangiitis (Wegener\u2019s) with HLA-DPB1*04 and SEMA6A gene variants: Evidence from genome-wide analysis","volume":"65","author":"Xie","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1136\/annrheumdis-2015-207601","article-title":"Genetic variants in ANCA-associated vasculitis: A meta-analysis","volume":"75","author":"Rahmattulla","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatology"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Cao, Y., Yang, J., Colby, K., Hogan, S.L., Hu, Y., Jennette, C.E., Berg, E.A., Zhang, Y., Jennette, J.C., and Falk, R.J. (2012). High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042783"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.mcp.2016.08.009","article-title":"Genetics and pathophysiology of granulomatosis with polyangiitis (GPA) and its main autoantigen proteinase 3","volume":"30","author":"Relle","year":"2016","journal-title":"Mol. Cell. Probes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1172\/JCI40034","article-title":"Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis","volume":"120","author":"Ciavatta","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1681\/ASN.2016050548","article-title":"Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis","volume":"28","author":"Jones","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2353\/ajpath.2009.080458","article-title":"Experimental autoimmune vasculitis: An animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis","volume":"174","author":"Little","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1365-2249.2000.01205.x","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) but not granulocyte colony-stimulating factor (G-CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro","volume":"120","author":"Hellmich","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1361.041","article-title":"Activation, apoptosis, and clearance of neutrophils in Wegener\u2019s granulomatosis","volume":"1051","author":"Limburg","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ma, T.T., Huang, Y.M., Wang, C., Zhao, M.H., and Chen, M. (2014). Coagulation and fibrinolysis index profile in patients with ANCA-associated vasculitis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097843"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ekir.2019.12.018","article-title":"Narrative Review of Hypercoagulability in Small-Vessel Vasculitis","volume":"5","author":"Claudel","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"i59","DOI":"10.1136\/ard.2010.138024","article-title":"Pathogenesis of ANCA-associated vasculitides","volume":"70","author":"Kallenberg","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nri.2017.105","article-title":"Neutrophil extracellular traps in immunity and disease","volume":"18","author":"Papayannopoulos","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/rheumatology\/kez089","article-title":"The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis","volume":"58","author":"Hattanda","year":"2019","journal-title":"Rheumatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/cei.12654","article-title":"Neutrophil extracellular traps can activate alternative complement pathways","volume":"181","author":"Wang","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/ar2923","article-title":"T cells in ANCA-associated vasculitis: What can we learn from lesional versus circulating T cells?","volume":"12","author":"Wilde","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.semnephrol.2017.05.016","article-title":"ANCA-Associated Vasculitis: Pathogenesis, Models, and Preclinical Testing","volume":"37","author":"Hutton","year":"2017","journal-title":"Semin. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fimmu.2014.00432","article-title":"T cell-macrophage interactions and granuloma formation in vasculitis","volume":"5","author":"Hilhorst","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.autrev.2018.08.006","article-title":"Th17 cells in renal inflammation and autoimmunity","volume":"18","author":"Dolff","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfz029","article-title":"T-lymphocyte in ANCA-associated vasculitis: What do we know? A pathophysiological and therapeutic approach","volume":"12","year":"2019","journal-title":"Clin. Kidney J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40425-019-0531-2","article-title":"NKG2D signaling certifies effector CD8 T cells for memory formation","volume":"7","author":"Perez","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/all.12088","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): State of the art","volume":"68","author":"Vaglio","year":"2013","journal-title":"Allergy"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000072987","article-title":"The Th1 and Th2 paradigm in ANCA-associated vasculitis","volume":"26","author":"Sanders","year":"2003","journal-title":"Kidney Blood Press. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humimm.2003.09.013","article-title":"Pathogenesis of diseases associated with antineutrophil cytoplasm autoantibodies","volume":"65","author":"Reumaux","year":"2004","journal-title":"Hum. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/ar392","article-title":"Staphylococcus aureus and Wegener\u2019s granulomatosis","volume":"4","author":"Popa","year":"2002","journal-title":"Arthritis Res. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Paroli, M., Caccavale, R., Fiorillo, M.T., Spadea, L., Gumina, S., Candela, V., and Paroli, M.P. (2022). The Double Game Played by Th17 Cells in Infection: Host Defense and Immunopathology. Pathogens, 11.","DOI":"10.3390\/pathogens11121547"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1681\/ASN.V1371977","article-title":"ANCA are pathogenic--oh yes they are!","volume":"13","author":"Falk","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3389\/fimmu.2020.00525","article-title":"Animal Models of ANCA Associated Vasculitis","volume":"11","author":"Shochet","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1073\/pnas.87.11.4115","article-title":"Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro","volume":"87","author":"Falk","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2249.1992.tb07934.x","article-title":"Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies","volume":"90","author":"Keogan","year":"1992","journal-title":"Clin. Exp. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/1529-0131(200006)43:6<1337::AID-ANR16>3.0.CO;2-M","article-title":"Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion","volume":"43","author":"Radford","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1681\/ASN.V125932","article-title":"Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1","volume":"12","author":"Kooten","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_78","first-page":"1695","article-title":"Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat","volume":"149","author":"Heeringa","year":"1996","journal-title":"Am. J. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.1995.58","article-title":"Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies","volume":"47","author":"Kobayashi","year":"1995","journal-title":"Kidney Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1084\/jem.177.4.905","article-title":"Antimyeloperoxidase-associated proliferative glomerulonephritis: An animal model","volume":"177","author":"Brouwer","year":"1993","journal-title":"J. Exp. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/rheumatology\/ken321","article-title":"Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis","volume":"47","author":"Gao","year":"2008","journal-title":"Rheumatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrneph.2012.108","article-title":"Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis","volume":"8","author":"Chen","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1081-1206(10)61400-7","article-title":"Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement","volume":"93","author":"Bansal","year":"2004","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.ajkd.2005.01.001","article-title":"Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs","volume":"45","author":"Schlieben","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1681\/ASN.2006020108","article-title":"Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis","volume":"17","author":"Ruth","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00281-014-0431-y","article-title":"B cell-mediated pathogenesis of ANCA-mediated vasculitis","volume":"36","author":"Jennette","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000503969","article-title":"The Presence of Renal IgG Deposits in Necrotizing Crescentic Glomerulonephritis Associated with ANCA Is Not Related to Worse Renal Clinical Outcomes","volume":"6","author":"Dudreuilh","year":"2020","journal-title":"Kidney Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00005792-199411000-00005","article-title":"Wegener\u2019s granulomatosis: Studies in eighteen patients and a review of the literature. 1973","volume":"73","author":"Fauci","year":"1994","journal-title":"Medicine"},{"key":"ref_93","first-page":"e10","article-title":"Mechanisms of vasculitis: How pauci-immune is ANCA-associated renal vasculitis?","volume":"105","author":"Tervaert","year":"2007","journal-title":"Nephron Exp. Nephrol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Hao, J., Meng, L.Q., Xu, P.C., Chen, M., and Zhao, M.H. (2012). p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038317"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/art.41011","article-title":"Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"71","author":"Wu","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Ohlsson, S., Holm, L., Hansson, C., Ohlsson, S.M., Gunnarsson, L., Pettersson, A., and Skattum, L. (2019). Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218272"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"102424","DOI":"10.1016\/j.autrev.2019.102424","article-title":"Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside","volume":"19","author":"Brilland","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nephro.2019.04.001","article-title":"Complement inhibition in ANCA vasculitis","volume":"15","author":"Jayne","year":"2019","journal-title":"Nephrol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.biocel.2009.04.005","article-title":"Complement component 5a (C5a)","volume":"41","author":"Manthey","year":"2009","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/eji.201041350","article-title":"TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2","volume":"41","author":"Raby","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"R142","DOI":"10.1186\/ar4604","article-title":"The interaction between C5a and sphingosine-1-phosphate in neutrophils for antineutrophil cytoplasmic antibody mediated activation","volume":"16","author":"Hao","year":"2014","journal-title":"Arthritis Res. Ther. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/ki.2012.371","article-title":"Complement is crucial in the pathogenesis of ANCA-associated vasculitis","volume":"83","author":"Kallenberg","year":"2013","journal-title":"Kidney Int."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clim.2016.11.013","article-title":"The functional activities of complement factor H are impaired in patients with ANCA-positive vasculitis","volume":"175","author":"Chen","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3389\/fimmu.2018.00559","article-title":"Complement Factor H Inhibits Anti-Neutrophil Cytoplasmic Autoantibody-Induced Neutrophil Activation by Interacting with Neutrophils","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cei.13051","article-title":"Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"191","author":"Cheng","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10157-018-1634-7","article-title":"Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis","volume":"23","author":"Choi","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s10067-019-04636-9","article-title":"Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: Retrospective cohort study","volume":"38","author":"Garcia","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-0038-1669454","article-title":"Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)","volume":"39","author":"Nguyen","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/art.21250","article-title":"Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome","volume":"52","author":"Sinico","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.autrev.2014.08.017","article-title":"Granulomatosis with polyangiitis (Wegener): Clinical aspects and treatment","volume":"13","author":"Comarmond","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): Monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"iii84","DOI":"10.1093\/rheumatology\/kez570","article-title":"Eosinophilic granulomatosis with polyangiitis: Understanding the disease and its management","volume":"59","author":"Trivioli","year":"2020","journal-title":"Rheumatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0","article-title":"Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome","volume":"44","author":"Kiene","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10875-013-9898-x","article-title":"Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis","volume":"33","author":"Tsurikisawa","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/rheumatology\/kev242","article-title":"First report of FIP1L1-PDGFRalpha-positive eosinophilic granulomatosis with polyangiitis","volume":"54","author":"Emmi","year":"2015","journal-title":"Rheumatolology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/rheumatology\/ken033","article-title":"Eotaxin-3 is involved in Churg-Strauss syndrome--a serum marker closely correlating with disease activity","volume":"47","author":"Polzer","year":"2008","journal-title":"Rheumatolology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1182\/blood-2010-02-267542","article-title":"Interleukin-25: A cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome","volume":"116","author":"Terrier","year":"2010","journal-title":"Blood"},{"key":"ref_122","first-page":"S23","article-title":"Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome","volume":"29","author":"Jakiela","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7861\/clinmedicine.17-1-60","article-title":"ANCA-associated vasculitis","volume":"17","author":"Yates","year":"2017","journal-title":"Clin. Med. (Lond.)"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ckj\/sfv020","article-title":"The kidneys and ANCA-associated vasculitis: From pathogenesis to diagnosis","volume":"8","author":"Rowaiye","year":"2015","journal-title":"Clin. Kidney J."},{"key":"ref_125","first-page":"189","article-title":"Upper respiratory tract symptoms, renal involvement and vasculitis: A case report and review of wegener granulomatosis","volume":"2","author":"Said","year":"2010","journal-title":"J. Clin. Med. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.otorri.2011.09.002","article-title":"Otolaryngologic manifestations of systemic vasculitis","volume":"63","year":"2012","journal-title":"Acta Otorrinolaringol. Esp."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.autrev.2017.05.008","article-title":"Interstital lung disease in ANCA vasculitis","volume":"16","author":"Alba","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12177-009-9044-4","article-title":"Ocular disease in patients with ANCA-positive vasculitis","volume":"3","author":"Watkins","year":"2009","journal-title":"J. Ocul. Biol. Dis. Infor."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/BOR.0000000000000346","article-title":"Approach to cutaneous vasculitides with special emphasis on small vessel vasculitis: Histopathology and direct immunofluorescence","volume":"29","author":"Demirkesen","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1586\/14737175.2016.1165095","article-title":"Neurological manifestations in ANCA-associated vasculitis\u2014Assessment and treatment","volume":"16","author":"Wludarczyk","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/rheumatology\/37.4.387","article-title":"Severe intestinal involvement in Wegener\u2019s granulomatosis: Report of two cases and review of the literature","volume":"37","author":"Storesund","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.mayocp.2018.02.010","article-title":"Risk of Cardiovascular Disease and Venous Thromboembolism among Patients with Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study","volume":"93","author":"Berti","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/art.11075","article-title":"Wegener\u2019s Granulomatosis Etanercept Trial Research G: Limited versus severe Wegener\u2019s granulomatosis: Baseline data on patients in the Wegener\u2019s granulomatosis etanercept trial","volume":"48","author":"Stone","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.berh.2009.02.004","article-title":"Churg-Strauss angiitis","volume":"23","author":"Sinico","year":"2009","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9343(03)00359-0","article-title":"Churg-Strauss syndrome: Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists","volume":"115","author":"Keogh","year":"2003","journal-title":"Am. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.128.6.2453","article-title":"Suppression of human B lymphocyte function by cyclophosphamide","volume":"128","author":"Cupps","year":"1982","journal-title":"J. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","article-title":"An interdisciplinary approach to the care of patients with Wegener\u2019s granulomatosis: Long-term outcome in 155 patients","volume":"43","author":"Beuge","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: An analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Von Borstel, A., Abdulahad, W.H., Dekkema, G., Rutgers, A., Stegeman, C.A., Veldman, J., Heeringa, P., and Sanders, J.S. (2020). Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235743"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14712598.2020.1748597","article-title":"Rituximab treatment of ANCA-associated vasculitis","volume":"20","author":"Raffray","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B Cells and Plasma Cells in Autoimmune Diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","article-title":"B cell therapy in ANCA-associated vasculitis: Current and emerging treatment options","volume":"14","author":"McClure","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/rheumatology\/kez640","article-title":"Rituximab for maintenance of remission in ANCA-associated vasculitis: Expert consensus guidelines","volume":"59","author":"Tieu","year":"2020","journal-title":"Rheumatology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.41501","article-title":"Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia from Rituximab for Autoimmune Disease","volume":"73","author":"Zonozi","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: Golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. Reply","volume":"382","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","article-title":"Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Teixeira","year":"2019","journal-title":"RMD Open"},{"key":"ref_159","first-page":"952","article-title":"Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis","volume":"77","author":"Emmi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/keab046","article-title":"Rituximab for eosinophilic granulomatosis with polyangiitis: A systematic review of observational studies","volume":"60","author":"Menditto","year":"2021","journal-title":"Rheumatology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"102737","DOI":"10.1016\/j.autrev.2020.102737","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of Biologics to Treat Relapsing and\/or Refractory Eosinophilic Granulomatosis with Polyangiitis: Data from a European Collaborative Study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_164","unstructured":"Terrier, B., de Moreuil, C., and Bonnotte, B. (2021). Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: A double-blind, randomized, controlled trial. Arthritis Rheum., 73."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0165-2478(94)00212-A","article-title":"Expression of the complement C5a anaphylatoxin receptor (C5aR) on non-myeloid cells","volume":"44","author":"Wetsel","year":"1995","journal-title":"Immunol. Lett."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Bekker, P., Dairaghi, D., Seitz, L., Leleti, M., Wang, Y., Ertl, L., Baumgart, T., Shugarts, S., Lohr, L., and Dang, T. (2016). Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164646"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive Treatment with Avacopan, an Oral C5a Receptor Inhibitor, in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis. Reply","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/mrcr\/rxac029","article-title":"Anti-neutrophil cytoplasmic antibody-associated vasculitis complicated by thrombotic microangiopathy with posterior reversible encephalopathy syndrome successfully treated with eculizumab: A case report","volume":"6","author":"Kitamura","year":"2022","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s11739-017-1636-6","article-title":"Complement blockade in ANCA-associated vasculitis: An index case, current concepts and future perspectives","volume":"12","author":"Manenti","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/rheumatology\/kez190","article-title":"Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab","volume":"58","author":"Ribes","year":"2019","journal-title":"Rheumatololgy"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(17)31963-3","article-title":"Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: A phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial","volume":"390","author":"Riedl","year":"2017","journal-title":"Lancet"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2222.2011.03854.x","article-title":"Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor","volume":"42","author":"Molfino","year":"2012","journal-title":"Clin. Exp. Allergy"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1159\/000514505","article-title":"Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab","volume":"182","author":"Tsurikisawa","year":"2021","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejim.2021.08.021","article-title":"Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis","volume":"95","author":"Arismendi","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2020.09.025","article-title":"Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase","volume":"9","author":"Caminati","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/1\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:59:40Z","timestamp":1760122780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/1\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":180,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["antib12010025"],"URL":"https:\/\/doi.org\/10.3390\/antib12010025","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]}}}